AI-generated analysis. Always verify with the original filing.
ArriVent BioPharma, Inc. (AVBP), a clinical-stage biopharmaceutical company, reported a net loss of $166.3 million for FY 2025, up 106.6% from $80.5 million in FY 2024, driven by intensified R&D investments in its lead candidate firmonertinib and early-stage programs. Total operating expenses surged to $177.5 million from $94.3 million YoY, with R&D expenses comprising $153.4 million (up 94.1%) due to Phase 3 trials FURVENT ($48.7M) and FURTHER ($9.8M), plus $55.5M in early-stage programs including a $40M upfront for ARR-217 licensing. G&A rose 58.0% to $24.2M from increased personnel and professional fees. No revenue was generated as the company remains pre-commercialization. Balance sheet strengthened with $333.2M total assets, including $332.9M current assets ($45.5M cash equivalents, $267.3M short-term investments). Stockholders' equity grew to $307.2M. Cash burn intensified with $160.6M used in operations (vs. $70.2M prior year), offset by $203.1M financing inflows from equity offerings. With $312.8M in cash/investments, runway extends beyond 12 months, supporting ongoing Phase 3 trials expecting topline data mid-2026.
ArriVent BioPharma reported FY 2025 net loss of $166.3M, widening 106.6% from $80.5M in 2024 amid accelerated clinical development. Operating loss reached $177.5M (vs. $94.3M prior year), with no revenue as pre-commercial. Total assets grew to $333.2M from $274.9M, driven by equity raises yielding $203.1M net financing cash. Cash burn escalated with $160.6M used in operations (up from $70.2M), reflecting R&D ramp-up. Stockholders' equity expanded to $307.2M, supported by $711.8M additional paid-in capital. EPS diluted to -$4.00 from -$2.56 YoY on 38.5M weighted shares.
No revenue generated in FY 2025 or 2024, consistent with clinical-stage status. Pipeline focus on firmonertinib (Phase 3 FURVENT/ALPACCA trials) and ARR-217 (Phase 1) precludes commercialization. R&D allocation: firmonertinib $67.6M (FURVENT $48.7M), early-stage $55.5M (Lepu upfront $40M). No geographic revenue split applicable.
Pre-revenue, no gross margins. Operating margin N/A; expenses dominated by R&D (86.4% of opex, up from 83.7%). G&A 13.6% of opex. Net loss per share -$4.00 reflects 22.3% share count increase YoY. Stock-based comp $12.5M (7.0% of opex) up from $3.2M, tied to headcount growth to 77 employees.
Operating cash use $160.6M (vs. $70.2M), driven by $153.4M R&D. Investing outflow $71.2M (net investments). Financing inflow $203.1M from ATM ($122.2M), July offering ($80.5M). Ending cash/investments $312.8M ($45.5M cash equiv., $267.3M short-term). Total liabilities minimal $25.9M (accrued $20.0M). No debt drawn; $75M facility available.
Management projects continued losses with $312.8M runway beyond 12 months. Priorities: FURVENT topline mid-2026, ALPACCA enrollment (480 patients), ARR-217 Phase 1. Risks include trial delays, milestone payments (Allist up to $765M, Lepu $1.17B), cash needs for commercialization. BIOSECURE Act may impact China manufacturing reliance.
EPS
-$4.00
Net Income
-$166.3M